Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Ord Shs KANT

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors

GlobeNewswire April 12, 2023

Kineta to Present at 22nd Annual Needham Healthcare Conference

GlobeNewswire April 3, 2023

Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2023

Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023

GlobeNewswire March 22, 2023

Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 8, 2023

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target

GlobeNewswire March 6, 2023

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

GlobeNewswire March 1, 2023

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

GlobeNewswire December 5, 2022

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

GlobeNewswire November 14, 2022

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

GlobeNewswire November 10, 2022

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

GlobeNewswire August 29, 2022

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

GlobeNewswire August 4, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX

PR Newswire July 6, 2022

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Business Wire July 5, 2022

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Business Wire June 7, 2022

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates YMTX, GTYH, HR, POLY

PR Newswire June 7, 2022

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

GlobeNewswire June 6, 2022

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

GlobeNewswire May 12, 2022

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

GlobeNewswire March 24, 2022

Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring

GlobeNewswire February 17, 2022